FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileOdyssey Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ODTX
Odyssey Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Odyssey Therapeutics, Inc. (ODTX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisODTX
ODTX
Odyssey Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ODTX
  1. Home
  2. Stocks
  3. Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc.

🇺🇸ODTX•NASDAQ

Odyssey Therapeutics, Inc.

🇺🇸ODTX•NASDAQ
Market cap
$912.33M

Your view on ODTX

Mkt Cap
$912.33M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Odyssey Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Gary D. Glick
Headquarters
51 Sleeper Street, Boston, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Gary D. Glick
Headquarters
51 Sleeper Street, Boston, MA, US
Description

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases.

Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis.

Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells.

Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Odyssey Therapeutics, Inc.. Starting points for Odyssey Therapeutics, Inc.: EPS -$3.71, beta 1.43 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Odyssey Therapeutics, Inc.. Trailing twelve-month EPS for Odyssey Therapeutics, Inc. stands at -$3.71. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
Analysts' target$36.60average of 5 firms, last 12 months
Current price—

Buy

Targets, low to high

$36.60

Low $27.00

Middle $40.00

High $44.00

Analyst ratings

2 ratings
  • Strong Buy0
  • Buy2
  • Hold0
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$1.09−$1.18−$5.87−$4.44
Lowest estimate−$1.21−$1.26−$6.05−$4.88
Highest estimate−$1.01−$1.10−$5.77−$3.55
Number of analysts4356
A year ago—−$6.771−$3.151—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$0.00$0.00$2.98M$2.98M
Lowest estimate$0.00$0.00$2.98M$2.98M
Highest estimate$0.00$0.00$2.98M$2.98M
Number of analysts0077
A year ago—$0.00$2.98M—
Growth vs a year ago——+0.0%—
Recent rating and target changes (7)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Odyssey Therapeutics, Inc.. Odyssey Therapeutics, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ODTX20 companies · 8 funds
Compare ODTX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
ACRSAclaris Therapeutics, Inc.HealthcareBiotechnology$555.1M
AGMBAgomAb Therapeutics N.V. American Depositary SharesHealthcareBiotechnology$286.6M
ALMSAlumis Inc. Common StockHealthcareBiotechnology$568.9M
ANABAnaptysBio, Inc.HealthcareBiotechnology$1.4B
IMUXImmunic, Inc.HealthcareBiotechnology$102.6M
ORKAOruka Therapeutics, Inc.HealthcareBiotechnology$6.5B
PTGXProtagonist Therapeutics, Inc.HealthcareBiotechnology$8.3B
SYRESpyre Therapeutics, Inc.HealthcareBiotechnology$9.6B
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PPCBPropanc Biopharma Inc. Common StockHealthcareNASDAQ$1.8M
PPTDFPeptiDream Inc.HealthcareOTC$1.1B
PRAXPraxis Precision Medicines, Inc.HealthcareNASDAQ$8.5B
PREDQPredictive Discovery LimitedHealthcareOTC$2,996
PREV.CNPreveCeutical Medical Inc.HealthcareCNQ$11.7M
PRLDPrelude Therapeutics IncorporatedHealthcareNASDAQ$191.0M
PRMEPrime Medicine, Inc.HealthcareNASDAQ$694.9M
PRNAFAlterity Therapeutics LimitedHealthcareOTC$109.8M
PROKProKidney Corp.HealthcareNASDAQ$349.7M
PROTProteonomix, Inc.HealthcareOTC$791
PRQRProQR Therapeutics N.V.HealthcareNASDAQ$155.2M
PRRUFImmutep LimitedHealthcareOTC$368.0M
ETFs holding Odyssey Therapeutics, Inc.
TickerFundFund assets% of the fund
IWMiShares Russell 2000 ETF$76.6B in assets0.01%
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
VXFVanguard Extended Market ETF$30.2B in assets0.00%
VTWOVanguard Russell 2000 ETF$16.6B in assets0.01%
VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.01%
RSSLGlobal X - Russell 2000 ETF$1.4B in assets0.01%
AVSCAvantis U.S. Small Cap Equity ETF$3.2B in assets0.01%
VTWVVanguard Russell 2000 Value ETF$1.3B in assets0.01%

Largest holders first, then the funds most concentrated in ODTX.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Odyssey Therapeutics, Inc., and how their positions are changing. At a $912.3M market value, institutional positions materially move Odyssey Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Odyssey Therapeutics, Inc.. Coverage tracks Odyssey Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Odyssey Therapeutics, Inc.

ODTX AnalysisFair
Past
5
Growth
2
Health
5
Profit
1
Value
1